GCA
NVAX icon

Greenwood Capital Associates’s Novavax NVAX Stock Holding History

Greenwood Capital Associates’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,511
Closed -$2.27M – 225
2021
Q1 		$2.27M Buy
+12,511
New +$2.49M 0.36% 70

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Greenwood Capital Associates's NVAX Position: Q2 2021 in Review

Greenwood Capital Associates sold out of Novavax (NVAX) in Q2 2021, closing a stake of 12,511 shares — an estimated $2.27M sold.

Greenwood Capital Associates first reported a position in NVAX in Q1 2021 and held it in 1 quarter. The position peaked at $2.27M in Q1 2021. 408 funds tracked by Wall St. Rank hold NVAX as of Q2 2021.

  • Greenwood Capital Associates reported no remaining Novavax position as of Q2 2021 after selling out during the quarter.
  • Greenwood Capital Associates sold 12,511 Novavax shares in Q2 2021, an estimated $2.27M.
  • Greenwood Capital Associates first reported a position in Novavax in Q1 2021 and held it in 1 quarter.
  • Greenwood Capital Associates's Novavax position peaked at $2.27M in Q1 2021.
  • 408 funds tracked by Wall St. Rank held Novavax as of Q2 2021.

Based on Greenwood Capital Associates's 13F filing for Q2 2021, filed 16 Aug 2021.